TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15025759

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO) administered at a constant low dose for up to 6 days
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO)
Number of subjects: 207
Study: 11687991

Group type: EXPERIMENTAL
Intervention: Trillium Biopassive Surface-coated oxygenator
Number of subjects: 30

Group type: COMPARATOR
Intervention: Uncoated oxygenator
Number of subjects: 30
Study: 9142028

Group type: EXPERIMENTAL
Intervention: 900 mL of albumin 5%
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 900 mL of Ringer's solution
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 900 mL of Ringer's acetate solution
Number of subjects: 18

Group type: COMPARATOR
Intervention: 900 mL blood withdrawal
Number of subjects: 18
Study: 8359178

Group type: EXPERIMENTAL
Intervention: 2 x 10 mg cisapride regimen
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 1 x 20 mg cisapride regimen
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 1 x 10 mg cisapride regimen
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Plasma concentrations of cisapride after 2 x 10 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Cisapride plasma concentrations greater than 60 ng.ml‐1
Number of subjects: 17
Study: 2820157

Group type: EXPERIMENTAL
Intervention: 240 g/die supplementary mackerel diet, no physical training
Number of subjects: 49

Group type: COMPARATOR
Intervention: Reducing diet (5,000 kJ/d), no mackerel diet, no physical training
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Reducing diet and a proportion of mackerels of 125 g/d, no physical training
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Reducing diet and mackerel diet 125 g/d as well as daily swimming training (20 to 30 min)
Number of subjects: 49
Study: 30569953

Group type: EXPERIMENTAL
Intervention: Colored eye drops
Number of subjects: 34

Group type: COMPARATOR
Intervention: Transparent eye drops
Number of subjects: 34
Study: 27798335

Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplements (MMNs)
Number of subjects: 4436

Group type: COMPARATOR
Intervention: Fe60F (60 mg Fe and 400 μg folic acid)
Number of subjects: 4436

Group type: EXPERIMENTAL
Intervention: Fe30F (30 mg Fe and 400 μg folic acid)
Number of subjects: 4436
Study: 25265895

Group type: EXPERIMENTAL
Intervention: DPI GSK961081 400 µg + oral placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: DPI GSK961081 1,200 µg + oral placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: DPI GSK961081 400 µg + oral propranolol 80 mg
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: DPI GSK961081 1,200 µg + oral propranolol 80 mg
Number of subjects: 41

Group type: COMPARATOR
Intervention: DPI and oral placebo
Number of subjects: 41
Study: 22858074

Group type: EXPERIMENTAL
Intervention: Fixed-dose combined isosorbide dinitrate/hydralazine (FDC I/H)
Number of subjects: 0
Study: 21094356

Group type: EXPERIMENTAL
Intervention: ICD for primary prevention
Number of subjects: 424
Study: 18678838

Group type: EXPERIMENTAL
Intervention: 21-gene assay
Number of subjects: 465
Study: 16583285

Group type: EXPERIMENTAL
Intervention: Committee-reviewed integrated examinations (2001-2002)
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Committee-reviewed integrated examinations (2002-2003)
Number of subjects: 520

Group type: COMPARATOR
Intervention: Departmentally/discipline based examinations (2000-2001)
Number of subjects: 520
Study: 14557961

Group type: EXPERIMENTAL
Intervention: Clarithromycin (500-1000 mg), Ethambutol (25 mg/kg), Rifampin (600 mg) 3 times per week
Number of subjects: 18
Study: 10892533

Group type: COMPARATOR
Intervention: Flyer about a worksite dietary intervention
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: Flyer plus personalized hand-signed letter with general population heart disease risk statistics
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: Flyer plus personalized hand-signed letter with Hispanic heart disease risk statistics
Number of subjects: 561
Study: 8990504

Group type: EXPERIMENTAL
Intervention: Betamethasone valerate (Betnovate)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Calcipotriol (Daivonex)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pure nanocolloid gel
Number of subjects: 10
Study: 1333899

Group type: EXPERIMENTAL
Intervention: Absolute curative resection
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Relative curative resection
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Relative non-curative resection
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Absolute non-curative resection
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Preoperative TAE (Transarterial Embolization)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Non-TAE
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: PSE (Percutaneous Sclerotherapy)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Hepatectomy after PSE
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Reresection in recurrent HCC
Number of subjects: 121

Group type: COMPARATOR
Intervention: TAE in recurrent HCC
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Continuous intra-arterial infusion of 5-FU and lentinan with intermittent epirubicin
Number of subjects: 121
Study: 6379275

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic Acid (ASS) 100 mg/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 30220261

Group type: EXPERIMENTAL
Intervention: Spaced-PE (S-PE; 10 sessions over 8 weeks)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Massed-PE (M-PE; 10 sessions over 2 weeks)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Present-Centered Therapy (PCT; 10 sessions over 8 weeks)
Number of subjects: 326
Study: 29297076

Group type: EXPERIMENTAL
Intervention: Mechanically Expanded Valve (MEV)
Number of subjects: 912

Group type: COMPARATOR
Intervention: Self-Expanding Valve (SEV)
Number of subjects: 912
Study: 26289619

Group type: EXPERIMENTAL
Intervention: Avenanthramides (AVA) supplementation (9.2 mg AVA per day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (0.4 mg AVA per day)
Number of subjects: 16
Study: 24316175

Group type: EXPERIMENTAL
Intervention: Lofexidine 0.2mg QID
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Lofexidine 0.8mg QID
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Cocaine (20mg and 40mg)
Number of subjects: 18
Study: 22002961

Group type: EXPERIMENTAL
Intervention: Gaboxadol (15 mg for subjects <65 years and 10 mg for subjects ≥65 years)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Gaboxadol
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 20174968

Group type: EXPERIMENTAL
Intervention: Vardenafil
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 17606555

Group type: EXPERIMENTAL
Intervention: Human milk intake (at least some human milk)
Number of subjects: 1057

Group type: EXPERIMENTAL
Intervention: Human milk intake (mean volume)
Number of subjects: 1057

Group type: EXPERIMENTAL
Intervention: Human milk intake (mean proportional volume)
Number of subjects: 1057
Study: 16446317

Group type: EXPERIMENTAL
Intervention: Cyclic schedule of ProMECE-CytaBOM chemotherapy (cyc-PC, 6 cycles)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Modified version of ProMECE-CytaBOM chemotherapy (seq-PC)
Number of subjects: 108
Study: 12544979

Group type: EXPERIMENTAL
Intervention: rh granulocyte colony-stimulating factor (Filgrastim)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10565592

Group type: EXPERIMENTAL
Intervention: Vigabatrin (VGB)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 8653312

Group type: EXPERIMENTAL
Intervention: Adrenalectomy (group A)
Number of subjects: 225

Group type: COMPARATOR
Intervention: No adrenalectomy (group B)
Number of subjects: 225
Study: 1712801

Group type: EXPERIMENTAL
Intervention: 6% low molecular weight hydroxyethyl starch (LMW HES)
Number of subjects: 18

Group type: COMPARATOR
Intervention: 4% albumin
Number of subjects: 18
Study: 6362943

Group type: EXPERIMENTAL
Intervention: Counseling by a specialist nurse
Number of subjects: 152

Group type: COMPARATOR
Intervention: Standard care from the surgical unit
Number of subjects: 152
Study: 31918579

Group type: EXPERIMENTAL
Intervention: Ceftobiprole
Number of subjects: 390

Group type: COMPARATOR
Intervention: Daptomycin
Number of subjects: 390
Study: 30684477

Group type: EXPERIMENTAL
Intervention: Mitral valve repair (MVr) with papillary muscle approximation (PMA)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Preoperative pulmonary artery systolic pressure
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: MV tenting area
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Symmetric MV tethering pattern
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Left ventricular end-diastolic diameter
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: MV tenting area ≥ 3.1 cm2 and left ventricular end-diastolic diameter ≥ 64 mm
Number of subjects: 48
Study: 27748212

Group type: EXPERIMENTAL
Intervention: Addressed condition
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Overhearing Two Adults condition
Number of subjects: 53

Group type: COMPARATOR
Intervention: Overhearing Classroom condition
Number of subjects: 53
Study: 28327266

Group type: EXPERIMENTAL
Intervention: Xylitol (8g per 200 mL milk once per day)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Xylitol (4g per 100 mL milk twice per day)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Sorbitol (8g per 200 mL milk once per day)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Sorbitol (4g per 100 mL milk twice per day)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Sucrose (8g per 200 mL milk once per day)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Xylitol (once per day)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Xylitol (twice per day)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Sorbitol (once per day)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Sorbitol (twice per day)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Sucrose (once per day)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Xylitol vs Sucrose
Number of subjects: 153

Group type: COMPARATOR
Intervention: Xylitol vs Sorbitol
Number of subjects: 153
Study: 25150004

Group type: EXPERIMENTAL
Intervention: Behaviour Change Techniques (BCTs) including intention formation, barrier identification, specific goal setting, instruction, general encouragement, self-monitoring of behaviour, social support, review of behavioural goals, and relapse prevention.
Number of subjects: 22
Study: 21711438

Group type: EXPERIMENTAL
Intervention: HAL-BLC
Number of subjects: 362

Group type: COMPARATOR
Intervention: WLC
Number of subjects: 362
Study: 19171274

Group type: EXPERIMENTAL
Intervention: Arthroscopic intervention of the first MTP joint (group 1)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Medical treatment alone (group 2)
Number of subjects: 28
Study: 17145137

Group type: EXPERIMENTAL
Intervention: 50 mg T enanthate
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: 100 mg T enanthate
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: 300 mg T enanthate
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo (saline) injection
Number of subjects: 57
Study: 15824416

Group type: EXPERIMENTAL
Intervention: Tam-IVF
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: TamFSH-IVF
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Letrozole-IVF
Number of subjects: 60

Group type: COMPARATOR
Intervention: IVF (combined TamFSH-IVF and Letrozole-IVF)
Number of subjects: 60
Study: 11719309

Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg/d for Week 1; 400 mg/d for Weeks 2 to 4)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 157

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study: 9387176

Group type: EXPERIMENTAL
Intervention: Pressure-ridge Molteno implant
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard Molteno implant with suture ligation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Suture-ligation implant group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pressure-ridge implant group
Number of subjects: 30
Study: 7935033

Group type: EXPERIMENTAL
Intervention: 0.6 mg/day of conjugated equine oestrogen (CEE) cyclically + 5 mg of medroxy‐progesterone acetate (MPA) for last 12 days
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 50 micrograms/day of transdermal oestradiol cyclically + 5 mg of medroxy‐progesterone acetate (MPA) for last 12 days
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 0.625 mg/day of CEE + 5 mg/day of MPA uninterruptedly
Number of subjects: 36

Group type: COMPARATOR
Intervention: Treatment-free control group
Number of subjects: 36
Study: 3513821

Group type: EXPERIMENTAL
Intervention: Grafted with HLA-A and HLA-B antigen matched material
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not grafted with matched material)
Number of subjects: 40
Study: 29952241

Group type: EXPERIMENTAL
Intervention: Vibration stimulus (n = 14), low-frequency and low-magnitude (27-32 Hz, 0.3 g), 20 minutes, 3 times per week for 12 weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Usual care control (n = 17)
Number of subjects: 31
Study: 27157469

Group type: EXPERIMENTAL
Intervention: 20 g soy protein isolate (SP20)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 40 g soy protein isolate (SP40)
Number of subjects: 8

Group type: COMPARATOR
Intervention: 0 g soy protein isolate (SP0)
Number of subjects: 8
Study: 24983201

Group type: EXPERIMENTAL
Intervention: Gender-concordant intervention
Number of subjects: 216
Study: 24170641

Group type: EXPERIMENTAL
Intervention: Low-calorie diet (800 kcal/day) for 28 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 20
Study: 21380981

Group type: EXPERIMENTAL
Intervention: Low-Intensity Exercise (LIEX)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: High-Intensity Exercise (HIEX)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 45
Study: 18312089

Group type: EXPERIMENTAL
Intervention: Guglielmi detachable coils (GDCs)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Short-term follow-up angiograms
Number of subjects: 92
Study: 16562415

Group type: EXPERIMENTAL
Intervention: Web-based survey
Number of subjects: 700

Group type: COMPARATOR
Intervention: Telephone interview
Number of subjects: 700
Study: 12686247

Group type: EXPERIMENTAL
Intervention: Post-LASIK group
Number of subjects: 32
Study: 10928300

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional agents and calcium channel blockers
Number of subjects: 0
Study: 9370847

Group type: EXPERIMENTAL
Intervention: Whitacre 25G
Number of subjects: 681

Group type: EXPERIMENTAL
Intervention: Polymedic 25G
Number of subjects: 681

Group type: EXPERIMENTAL
Intervention: Sprotte 24G
Number of subjects: 681

Group type: EXPERIMENTAL
Intervention: Polymedic 24G
Number of subjects: 681
Study: 1555618

Group type: EXPERIMENTAL
Intervention: ST recordings in the coronary care unit (CCU) performed for 24 hours
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: ST recordings before discharge during ambulation in hospital (4-6 days after admission)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Ambulatory monitoring after 1 month
Number of subjects: 198
Study: 6753245

Group type: EXPERIMENTAL
Intervention: Misonidazole (400 mg/m2) administered with each of the 30 fractions of radiotherapy
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo administered with each of the 30 fractions of radiotherapy
Number of subjects: 102
Study: 31719145

Group type: EXPERIMENTAL
Intervention: Tubacin
Number of subjects: 0
Study: 28912639

Group type: EXPERIMENTAL
Intervention: Levobupivacaine only (0.5%) 0.4 mg·kg‐1
Number of subjects: 90

Group type: COMPARATOR
Intervention: Levobupivacaine (0.5%) 0.4 mg·kg‐1 + adrenaline (1:200,000)
Number of subjects: 90
Study: 25571997

Group type: EXPERIMENTAL
Intervention: Affective short-term message (ASM)
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: Cognitive long-term message
Number of subjects: 596

Group type: COMPARATOR
Intervention: No message control
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: Short-term cognitive message
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: Long-term affective message
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: Long-term cognitive message
Number of subjects: 596
Study: 24156304

Group type: EXPERIMENTAL
Intervention: VisThesia™
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Viscoat®
Number of subjects: 44
Study: 21610205

Group type: EXPERIMENTAL
Intervention: Gastric-retentive extended-release (ER) formulation (4 hours)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gastric-retentive extended-release (ER) formulation (6 hours)
Number of subjects: 0

Group type: COMPARATOR
Intervention: M-ER (comparator ER tablet)
Number of subjects: 0
Study: 19207348

Group type: EXPERIMENTAL
Intervention: School-based alcohol education intervention consisting of four interactive lessons, booklets for students and parents.
Number of subjects: 1686

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 1686
Study: 17457961

Group type: EXPERIMENTAL
Intervention: 120 mg GBE complexed with phosphatidylserine
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 120 mg GBE complexed with phosphatidylcholine
Number of subjects: 28

Group type: COMPARATOR
Intervention: 120 mg GBE
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 16449074

Group type: EXPERIMENTAL
Intervention: Occupational therapy plus one Botulinum Toxin A injection
Number of subjects: 41

Group type: COMPARATOR
Intervention: Occupational therapy only
Number of subjects: 41
Study: 14501381

Group type: EXPERIMENTAL
Intervention: 200 microg of selenized yeast
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 800 microg of selenized yeast
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selenized yeast (both doses)
Number of subjects: 0
Study: 10323688

Group type: EXPERIMENTAL
Intervention: 2 g of sulbactam‐ampicillin combination
Number of subjects: 1400

Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 1400
Study: 8904729

Group type: EXPERIMENTAL
Intervention: Examination group (high stress)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nonexamination group (low stress)
Number of subjects: 30
Study: 1930858

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 to 40 mg/day for 8 weeks)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Captopril (37.5 to 75 mg/day for 8 weeks)
Number of subjects: 36
Study: 7172738

Group type: EXPERIMENTAL
Intervention: Lotion V
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lotion K
Number of subjects: 0
Study: 31808996

Group type: EXPERIMENTAL
Intervention: Pharmacogenetic testing prior to statin initiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Statin therapy
Number of subjects: 0
Study: 29794609

Group type: EXPERIMENTAL
Intervention: Automated internet-based pain coping skills training (PCST) program
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Online education and PCST
Number of subjects: 144

Group type: COMPARATOR
Intervention: Online education only (comparison group)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: PCST group
Number of subjects: 144
Study: 28741716

Group type: EXPERIMENTAL
Intervention: LMA™ Proseal (PLMA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LMA™ Supreme (SLMA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lateral position with pneumoperitoneum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adverse events
Number of subjects: 0
Study: 26614499

Group type: EXPERIMENTAL
Intervention: 2-tablet dose of IR/ER HB/APAP under fed (high- and low-fat) conditions
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: 3-tablet dose of IR/ER HB/APAP under fed (high- and low-fat) conditions
Number of subjects: 78

Group type: COMPARATOR
Intervention: High-fat meal
Number of subjects: 78

Group type: COMPARATOR
Intervention: Low-fat meal
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Treatment-emergent adverse events (TEAEs)
Number of subjects: 78
Study: 24035949

Group type: EXPERIMENTAL
Intervention: Rocuronium pretreatment followed by succinylcholine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Succinylcholine alone
Number of subjects: 60
Study: 21635709

Group type: EXPERIMENTAL
Intervention: Tamoxifen (5 years monotherapy)
Number of subjects: 8010

Group type: EXPERIMENTAL
Intervention: Letrozole (5 years monotherapy)
Number of subjects: 8010

Group type: EXPERIMENTAL
Intervention: Tamoxifen for 2 years followed by Letrozole for 3 years
Number of subjects: 8010

Group type: EXPERIMENTAL
Intervention: Letrozole for 2 years followed by Tamoxifen for 3 years
Number of subjects: 8010
Study: 18503103

Group type: EXPERIMENTAL
Intervention: Lactate analysis (n=1496)
Number of subjects: 2992

Group type: COMPARATOR
Intervention: pH analysis (n=1496)
Number of subjects: 2992
Study: 15665204

Group type: EXPERIMENTAL
Intervention: Aircast ankle brace
Number of subjects: 50

Group type: COMPARATOR
Intervention: Elastic support bandage
Number of subjects: 50
Study: 13679822

Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 11392406

Group type: EXPERIMENTAL
Intervention: Levodopa-carbidopa suspension in Ora Plus/Ora Sweet
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Levodopa-carbidopa suspension with ascorbic acid
Number of subjects: 15

Group type: COMPARATOR
Intervention: Levodopa-carbidopa suspension
Number of subjects: 15
Study: 8730003

Group type: EXPERIMENTAL
Intervention: Salmeterol (100 micrograms)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Beclomethasone (500 micrograms)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 1846438

Group type: EXPERIMENTAL
Intervention: Continuous schedule (daily estrogen and progestin)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sequential schedule (conjugated estrogen on days 1‐25, medroxyprogesterone acetate on days 16‐25)
Number of subjects: 48
Study: 6356630

Group type: EXPERIMENTAL
Intervention: tiaprofenic acid (daily dose 600 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: ibuprofen (daily dose 1200 mg)
Number of subjects: 60